spacer
home > pmps > summer 2002 > surfactant - therapy, excipient and humectant
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Surfactant - Therapy, Excipient and Humectant

Surfactant replacement therapy for the treatment and prevention of neonatal respiratory distress syndrome (RDS) has been a major success story in respiratory care over the past decade. Animal-derived and synthetic surfactants are now available commercially throughout the world and there are several others in development. Surfactants are currently providing a miracle-like contribution towards dramatically improving the survival rate of critically ill infants with less than 30 weeks' gestation.

However, these advances may well be overshadowed by progressions in formulation technology that will make synthetic surfactants available for a number of other conditions. After the first few days from birth, adequate surfactant function is vitally important for optimal lung function. Surfactant dysfunction arising from a variety of mechanisms may contribute to a number of conditions. Surfactant therapy has been examined in a number of these with varying effects.

They include acute respiratory distress syndrome (ARDS) (1), respiratory syncytial virus bronchiolitis in infants (2), chronic bronchitis (3), chronic obstructive pulmonary disease (4), asthma (5,15), respiratory infections (6) and cystic fibrosis (7). Understanding the different roles of endogenous surfactant and the dysfunctions observed in these conditions must be a consideration when designing an effective therapy. In addition to opposing surface tension forces within the alveolus to maintain airway stability, surfactant has also been reported to promote mucociliary clearance (8), bind or neutralise aeroallergens, pollens, bacteria and other particulates (9,10), and oppose airway oedema (11).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Derek Woodcock, Technical Services Director for Britannia Pharmaceuticals Ltd. Derek Woodcock is Technical Services Director for Britannia Pharmaceuticals Ltd., where he is responsible for the company's medical, clinical and development projects. Derek oversees specific technical projects from the formulation definition stage to clinical evaluation and registration.
He currently has technical responsibility for establishing Britannia's phospholipid and surfactant research, which also covers some novel delivery technologies for internal and out-licensing opportunities. In addition to technical expertise, he has particular knowledge in the area of drug licensing and registration.
Derek gained a BPharm degree in Pharmacy from The School of Pharmacy in London and an MBA from Kingston University. He is also a registered Pharmacist.

spacer
Derek Woodcock
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals and Nordic Nanovector have extended partnership for Betalutin® late stage manufacturing for B-cell non-Hodgkin lymphoma (NHL) treatment

The non-Hodgkin lymphoma (NHL) is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system
More info >>

White Papers

Life Cycle of an Analytical Method - a Case Study on the Monocyte Activation Test

Wickham Laboratories Limited

Pyrogens, a heterogeneous group of fever inducing contaminants, are comprised of microbial and non-microbial compounds; e.g. endotoxin (lipopolysaccharide, LPS) produced by Gram-negative bacteria, lipoteichoic acid (LTA) from Gram-positive bacteria, bacterial DNA (CpG-motive), endogenous pyrogens, virus and fungi particles or even fragments of packaging materials, plastic and dust. Contaminat ion wi th pyrogens in pharmaceutical products, biotherapeutics and on medical devices can lead to life threatening fever reactions. To ensure consumer safety, pyrogen testing is mandatory for parenteral products and medical devices.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement